ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Contents lists available at ScienceDirect 
ArtiÔ¨Åcial Intelligence in the Life Sciences 
journal homepage: www.elsevier.com/locate/ailsci 
Pharmaceutical patent landscaping: A novel approach to understand 
patents from the drug discovery perspective 
Yojana Gadiya a , b , c , ‚àó , Philip Gribbon a , b , Martin Hofmann-Apitius c , d , Andrea Zaliani a , b 
a Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, Hamburg 22525, Germany 
b Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Theodor Stern Kai 7, Frankfurt 60590, Germany 
c Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, Bonn 53113, Germany 
d Department of Bioinformatics, Fraunhofer Institute for Algorithms and ScientiÔ¨Åc Computing (SCAI), Schloss Birlinghoven, Sankt Augustin 53757, Germany 
a r t i c l e 
i n f o 
Keywords: 
Patent analysis 
Drug discovery 
Patent landscape 
Rare disease 
Alzheimer‚Äôs disease 
Drug repurposing 
Target importance 
a b s t r a c t 
Patents play a crucial role in the drug discovery process by providing legal protection for discoveries and in- 
centivising investments in research and development. By identifying patterns within patent data resources, re- 
searchers can gain insight into the market trends and priorities of the pharmaceutical and biotechnology indus- 
tries, as well as provide additional perspectives on more fundamental aspects such as the emergence of potential 
new drug targets. In this paper, we used the patent enrichment tool, PEMT, to extract, integrate, and analyse 
patent literature for rare diseases (RD) and Alzheimer‚Äôs disease (AD). This is followed by a systematic review 
of the underlying patent landscape to decipher trends and applications in patents for these diseases. To do so, 
we discuss prominent organisations involved in drug discovery research in AD and RD. This allows us to gain 
an understanding of the importance of AD and RD from speciÔ¨Åc organisational (pharmaceutical or university) 
perspectives. Next, we analyse the historical focus of patents in relation to individual therapeutic targets and 
correlate them with market scenarios allowing the identiÔ¨Åcation of prominent targets for a disease. Lastly, we 
identiÔ¨Åed drug repurposing activities within the two diseases with the help of patents. This resulted in identify- 
ing existing repurposed drugs and novel potential therapeutic approaches applicable to the indication areas. The 
study demonstrates the expanded applicability of patent documents from legal to drug discovery, design, and 
research, thus, providing a valuable resource for future drug discovery eÔ¨Äorts. Moreover, this study is an attempt 
towards understanding the importance of data underlying patent documents and raising the need for preparing 
the data for machine learning-based applications. 
1. Introduction 
Patent documents are considered crucial assets within the drug dis- 
covery domain as they allow the inventor rights over an invention for 
typically 20 years post Ô¨Åling. In the biomedical domain, these inven- 
tions could include information on drug formulation, dosage or eÔ¨Écacy, 
as well as information on the medicinal chemistry properties of leads or 
pre-clinical candidates. Moreover, the legal value of intellectual prop- 
erty in patent documents, and their distinctive function compared to 
scientiÔ¨Åc literature, makes patents crucial milestones in drug discovery 
and development [1] . Despite this, patent documents have been rela- 
tively untapped as a source to assist in scientiÔ¨Åc discovery and are used 
in the latter parts of drug discovery to assist investors in drafting new 
patents for their innovation or extension of existing patents in case of 
‚Äúme-too ‚Äù drugs [2] . Also, the use of legal phraseology within patent doc- 
uments requires experts in both patent drafting and patent analysis to 
‚àó Corresponding authors at: Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, Hamburg 22525, Germany. 
E-mail address: Yojana.Gadiya@itmp.fraunhofer.de (Y. Gadiya) . 
evaluate and understand the underlying content. As a result, patent liter- 
ature mining has developed into a specialised Ô¨Åeld that is closely linked 
with chemoinformatic analysis and commercial evaluation, meaning the 
appearance of patent sourced information is less common in publicly 
available scientiÔ¨Åc data resources. In the current context, we use the 
word ‚Äúpatent ‚Äù to indicate both patent applications and granted patents. 
Recently, there has been an increase in the attention given to 
patent documents as an aid to monitor advancements in drug dis- 
covery. This is seen in the Ô¨Åeld of oncology drug discovery, where 
patenting activity is intense, and patents oÔ¨Äer a window into the latest 
techniques in translational cancer therapies [3‚Äì5] . To support these 
eÔ¨Äorts, oncology-speciÔ¨Åc patent datasets have been catalogued by 
established patent oÔ¨Éces such as the USPTO Cancer Moonshot Patent 
Data ( https://www.uspto.gov/ip-policy/economic-research/research- 
datasets/cancer-moonshot-patent-data ). Moreover, there have been ef- 
forts in mining and ingesting patent-related information into knowledge 
https://doi.org/10.1016/j.ailsci.2023.100069 
Received 10 February 2023; Received in revised form 29 March 2023; Accepted 29 March 2023 
Available online 31 March 2023 
2667-3185/¬© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
graphs. One such example is the Chinese patent medicine (CPM) knowl- 
edge graph, where a natural language model (BERT) was used to extract 
biological entities (speciÔ¨Åcally chemicals, diseases, and conditions) from 
patent documents [6] . The resultant graph assisted in the identiÔ¨Åcation 
of disease gaps as well as summarising drug prescription trends in China. 
In addition to the extraction of patent-related information, the 
importance of exploring patent literature has attracted new market 
interest from scientiÔ¨Åc information vendors. The value of an exhaus- 
tive patent exploration process is signiÔ¨Åcant for the pharmaceutical 
industry, resulting in the establishment of commercial and open-source 
patent databases besides institutional oÔ¨Éces such as the United States 
Patent and Trademark OÔ¨Éce (USPTO), European Patent OÔ¨Éce (EPO), 
and Japan Patent OÔ¨Éce (JPO). The dominant commercial providers 
in this market are Clarivate ( https://clarivate.com/products/ip- 
intelligence/ip-data-and-apis/derwent-world-patents-index/ ) 
and 
CAS-SciÔ¨Ånder ( https://www.cas.org/solutions/cas-sciÔ¨Ånder-discovery- 
platform/cas-sciÔ¨Ånder ). Simultaneously, public chemical databases 
have also incorporated patent information for their catalogued chemi- 
cal collections. PubChem [7] has historically incorporated compound 
links to USPTO, while the European counterpart, ChEMBL, has de- 
veloped a stand-alone patent database (SureChEMBL) [8] based upon 
annotated biomedical entities which allow for searching a larger 
chemical space to inform drug discovery. Within the drug develop- 
ment domain, SureChEMBL represents one of the largest open-access 
resources of patents with its ability to extract data from independent 
patent oÔ¨Éces. Such databases have enabled researchers to systemat- 
ically assess, identify, and explore patterns within patent documents 
[ 9 , 10 ]. 
Patent documents can serve as a vast data source for machine learn- 
ing (ML) and artiÔ¨Åcial intelligence (AI) applications [11] . ML-based al- 
gorithms can be used to predict the success rate of patented compounds 
by incorporating clinical trial results. This could be also beneÔ¨Åcial for 
patent applicants in making R&D strategic decisions related to competi- 
tors. However, the unstructured nature of patent documents and their 
actual digital media, which are often in PDF format when downloaded 
from public repositories, also poses a challenge and as a result, manual 
curation is required to extract valuable information, such as bioactivity 
data, from these documents [12] . Therefore, there is an increasing need 
for tools for patent automatic analysis utilising language models (LM) to 
identify and extract relevant metadata for exhaustive patent data search. 
In 2022, we introduced PEMT, a patent enrichment tool that al- 
lows extraction of pharmaceutically relevant entities such as targets and 
chemicals of interest from patent documents [13] . This tool annotates 
modulators with patent information rather than providing an overview 
of the usability of the patents in drug discovery. This manuscript aims 
to guide readers through the tool‚Äôs implementation and, in doing so, 
highlight the role patent literature can play in driving decisions in the 
drug discovery process. We utilised knowledge graphs (KGs), which are 
graphical databases composed of aggregated literature and experimen- 
tal data, as the platform for demonstrating the utility of our analyses. For 
rare diseases, we utilised OrphaNet [14] , while for Alzheimer‚Äôs disease, 
we used the Human Brain Pharmacome [15] . By means of these KGs, 
we extracted data from the past two decades of chemical patent space 
and performed patent landscaping, which involved the identiÔ¨Åcation of 
patterns within patent documents. We start by identifying the commer- 
cial and non-commercial pharmaceutical originators based on the patent 
activity of their aÔ¨Éliated owners. Next, we performed a retrospective 
overview of targeted proteins from patent documents, to identify their 
importance in the drug development process at speciÔ¨Åc periods. Addi- 
tionally, we examined the impact clinical trials have had on the corre- 
sponding target prioritisation. Lastly, we examined the drug repurpos- 
ing aspect of pre-clinical small molecules and clinical stage drugs, high- 
lighting potential novel disease treatment options. Overall, this patent 
landscaping approach highlights the importance of analysing patents 
and their usefulness in making decisions during drug development 
eÔ¨Äorts. 
2. Methods 
In the initial sections, we discuss the KGs employed as data sources, 
explain the functioning of the PEMT tool, and outline the curation pro- 
cess necessary for standardising information from patent documents. Fi- 
nally, we provide information on the implementation details pertinent 
to the analysis. 
2.1. Knowledge graph selection 
We extracted data from two indication-speciÔ¨Åc semantically organ- 
ised KGs: OrphaNet and Human Brain Pharamcome (HBP). OrphaNet 
(accessed on 2021‚Äì11‚Äì01) is an open-source network that focuses on 
rare diseases and includes information on biological entities such as or- 
phan gene targets and drugs, as well as clinical entities such as clinical 
trials and biobanks [14] . In contrast, the Human Brain Pharmacome 
(HBP) is a publicly available biomedical knowledge graph representing 
neurodegenerative diseases with a particular focus on Alzheimer‚Äôs dis- 
ease [15] . The data in the graph is built on the Biological Expression 
Language (BEL) framework and includes information on proteins, bio- 
logical processes, and other relevant features [16] . 
2.2. Experimental and patent data extraction 
To expand the data resource with patent data, we used the PEMT 
tool [13] , which systematically retrieves patent documents using a list 
of genes or proteins. To do so, it extracts manually annotated and veri- 
Ô¨Åed chemical and biological modulators that have binding or functional 
eÔ¨Äects on proteins from ChEMBL and subsequently captures all patent 
documents related to the modulators using SureChEMBL. The patent 
documents collected are then Ô¨Åltered based on their pharmaceutical rel- 
evance and status (i.e. whether the patents are active or expired). Thus, 
the tool removed patent documents older than 20 years and only in- 
cluded those documents that were tagged with speciÔ¨Åc IPC code classes 
referenced in the publication [13] . These codes are alphanumeric codes 
assigned by oÔ¨Écials to patent documents and help in understanding the 
scope of the patent. 
2.3. Patent data harmonisation pipeline 
To aid systematic analysis, we developed data harmonisation and 
normalisation pipelines. In this pipeline, patent owner names were clas- 
siÔ¨Åed into three categories: ‚ÄúOrganisation ‚Äù, ‚ÄúAcquired ‚Äù, and ‚ÄúIndivid- 
uals ‚Äù. Organisations include patent owners that were part of compa- 
nies and universities, while Acquired owners are those that were within 
legacy entities which have been acquired or merged into larger Organ- 
isations. An example would be Dupont Pharmaceuticals, which Bris- 
tol Myers Squibb (BMS) acquired. Individuals are individuals who own 
a patent. Additionally, similar organisations were grouped for consis- 
tency. For example, all variations of Bristol Myers Squibb were mapped 
to Bristol Myers Squibb. This normalisation step allows for identifying 
all relevant patents from the same owner and has not been performed 
previously. 
2.4. Compound clinical stage annotation 
To annotate compounds based on their clinical trial stage, we utilised 
the information captured within ChEMBL. For each compound regis- 
tered in ChEMBL, an additional annotation is made based on whether 
the compound has been a clinical candidate and if so, at which stage. 
As a result, ChEMBL assigns phase numbers 0 - 4 where 0 indicates a 
compound being researched in the preclinical stage, 1 to 3 indicate the 
compound being tested in clinical trial phases I - III, and 4 indicates the 
compound has been approved by FDA and/or EMA. In our analysis, we 
make use of this ChEMBL data to identify compounds, with associated 
patents, that have been moved from the preclinical to the clinical setup 
within the drug discovery pipeline. 
2 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 1. Synopsis of the patenting landscape analysis . We collect all human proteins from the two biological networks relevant to diseases and symptoms. Using 
these proteins as a starting point, we run our PEMT tool and retrieve all associated modulators and patent documents based on predeÔ¨Åned conditions. Finally, using 
the patent document dataset, also referred to as patent corpora, we conduct deductive and exploratory analysis to uncover patterns within the dataset. 
2.5. Patent data clustering 
To cluster patent owners, we made use of a hierarchical approach 
where two or more owners are clustered together based on a distance 
metric from singletons to cluster groups in a bottom-to-top manner. 
This type of clustering allows creation of dendrograms that help es- 
tablish patent owner groups that belong to the same cluster. The dis- 
tance metric used in the clustering approach was the distance correlation 
which enabled in measuring the dependency between the two owners 
( Eq. (1) ). The clustering was achieved using Seaborn ‚Äòclustermap‚Äò pack- 
age ( https://seaborn.pydata.org/generated/seaborn.clustermap.html ). 
ùë• = 1 ‚àí 
(ùë¢ ‚àí ùë¢ ‚Ä≤) . (ùë£ ‚àí ùë£ ‚Ä≤)
||( ùë¢ ‚àí ùë¢ ‚Ä≤) ||‚ãÖ||( ùë£ ‚àí ùë£ ‚Ä≤) ||
(1) 
Eq. (1) . Distance correlation. The distance correlation is a metric 
used to clusters that have minimal distance together. In this equation, 
u‚Äô is the mean of vector u and x . y is the dot product of x and y . 
2.6. Target based publication data collection 
To extract publications relevant to targets of interest, we 
made use of open source platforms within NCBI Gene Browser 
( https://www.ncbi.nlm.nih.gov/gene/ ) to gather information on the hu- 
man targets. Through the link between the gene platform and PubMed 
( https://pubmed.ncbi.nlm.nih.gov/ ), we collected all relevant publica- 
tions related to a target. For our purposes, we clustered all the publi- 
cation found in a year together and used this statistics as the basis for 
understanding the research trend on targets. Moreover, we rescaled the 
publication counts to be between 0 and 1 using the min-max normaliser 
( Eq. (2) ). 
ùë• ‚Ä≤ = 
ùë• ‚àí ùëöùëñùëõ ( ùë• ) 
ùëöùëéùë• ( ùë• ) ‚àí ùëöùëñùëõ ( ùë• ) 
(2) 
Eq. (2) . Min-max normalizer. The min-max normalise allows us to 
scale the values to a deÔ¨Åne range. In this equation, x is an original value 
and x‚Äô is the normalized value. 
2.7. Data availability and implementation details 
To run our PEMT tool, we extracted human proteins that mod- 
ulate a disease or symptom from both graphs. The PEMT tool was 
run on a Windows operating system and was followed by the har- 
monisation pipeline mentioned in Section 2.3 . Additionally, within the 
collected patent documents, we found 131 patents in rare diseases 
and 705 patents in Alzheimer‚Äôs diseases with no associated owner. 
This is likely due to the quarterly updation of public databases like 
SureChEMBL, causing a lag in the time for updating. As a result, ad- 
ditional Ô¨Åltering was done to exclude patents with no owners from 
the study. Fig. 1 provides an overview of the process involved in col- 
lecting and analysing the patent dataset, referred to as the patent cor- 
pora, in the following sections. The data and the scripts used during 
this analysis can be found on GitHub at https://github.com/Fraunhofer- 
ITMP/Pharmaceutical-patent-landscaping. 
3. Results 
We analysed the patent extracted from 4314 to 10,237 proteins from 
OrphaNet and HBP respectively. In this analysis, we deÔ¨Åne ‚Äúrare dis- 
eases ‚Äù as diseases mentioned within the Orphanet database. In the fol- 
lowing section, details four subsections through which we explain how 
patent literature can be utilised in drug discovery. First, we provide an 
overview of the information collected from the patent corpora for each 
disease. Next, we retrospectively analyse the patent corpora unveiling 
leading organisations in drug research and discovery (R&D) for individ- 
ual diseases. Following this, we investigated case studies for selected tar- 
gets based on biological networks and examined their patenting trend. 
Lastly, we illustrate the usefulness of patent documents in identifying 
drug repurposing opportunities. 
3.1. Overview of the patent corpora 
In this section, we investigate the patent corpora of each disease and 
provide a statistical overview of the information collected within the 
patent corpora. This summary will provide insights into the scope of 
patenting activity within the disease area, denoting whether the patents 
are Ô¨Åled for pharmacological relevance or for formulation purposes. We 
will also examine and compare the number of patent documents that 
have been approved versus those still in the application pipeline. 
We retrieved 17,506 compound-patent pairs from the dataset, which 
included 585 compounds and 502 unique patent documents with the 
rare disease patent corpora. Out of the patents retrieved, 180 were 
granted patents, represented by documents with kind codes starting with 
B or E, while the rest were still in the application process, represented 
by documents with kind codes starting with A ( Fig. 2 A). Additionally, 
based on the IPC classiÔ¨Åcation, it was revealed that more than half of the 
patents were related to C07D ( https://www.wipo.int/classiÔ¨Åcations/ 
ipc/en/ITsupport/Version20170101/transformations/ipc/20170101/ 
en/htm/C07D.htm#C07D ), which includes heterocyclic compounds. 
Following this, 12% of patent documents were in the IPC code C07J 
(steroids), 7% were in code C07K (peptides), and 6% were in code 
A61P (speciÔ¨Åc therapeutic activity of chemical compounds or medicinal 
preparations) ( Fig. 2 B). 
Conversely, in the case of the Alzheimer‚Äôs disease patent corpora, 
we retrieved 76,321 compound-patent pairs that included 22,930 com- 
pounds and 13,181 unique patent applications. From these patents, 
3980 were granted (indicated by kind codes starting with either B or 
3 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 2. Patenting Landscape overview for Rare and Alzheimer‚Äôs Diseases . ( A) Rare disease patent application ratio denoting whether the patents have been 
granted (in grey) or are still pending (in blue). ( B) Logarithmic distribution of the rare disease patents based on the IPC classiÔ¨Åcation category. ( C) Alzheimer‚Äôs disease 
patent application ratio denoting whether the patents have been granted (in grey) or are still pending (in blue). D) Logarithmic distribution of the Alzheimer‚Äôs disease 
patents based on the IPC classiÔ¨Åcation category. 
E), while the remaining were still under the application process (in- 
dicated by kind codes starting with A) ( Fig. 2 C). Upon reviewing the 
IPC classiÔ¨Åcation of the patents, it was found that 70% of the docu- 
ments belonged to class C07D, representing patent applications men- 
tioning heterocyclic compounds. Alongside this class, other notable IPCs 
include C07C (representing acyclic and carboxylic compounds) with 7% 
of patent documents, A61P (representing a speciÔ¨Åc therapeutic activity 
of chemical compounds or medicinal preparations) with 5% of patent 
applications, and C07K (representing peptides) with 5% of patent appli- 
cations ( Fig. 2 D). 
Thus, RD and AD patent cohorts revealed two recurring patterns: 
i) a lower number of granted patents and ii) a dominance of ‚ÄúC07D 
coded ‚Äù patent applications. The observation that granted patents are 
approximately half of all applications Ô¨Åled is consistent with the statis- 
tics within the pharmaceutical domain generated by EPO ( https://new. 
epo.org/en/statistics-centre#/technologyÔ¨Åelds?code = 16 ). This Ô¨Åled- 
to-granted patents ratio can be attributed to several reasons. One of the 
reasons is the diÔ¨Éculty and expenditure involved in the research and 
development around patents. With the limited number of individuals re- 
viewing the documents, the search for potential competitiveness within 
pre-existing inventions is time-consuming ( https://www.epo.org/ 
learning/materials/inventors-handbook/protection/patents.html ). Ad- 
ditionally, the prevalence of C07D patents is likely due to the diver- 
sity provided by this class of compounds, which makes them a desirable 
candidate for drug discovery patent innovation compared to other com- 
pound classes [17] . 
3.2. Trends in the patenting landscape from the patent owners‚Äô perspective 
Next, we analysed the patenting activity for each disease to deter- 
mine the major pharmaceutical companies and academic institutions 
that have made signiÔ¨Åcant contributions to the R&D of potential drugs 
in the Ô¨Åeld. To do so, we leveraged the high-level patent owner classiÔ¨Å- 
cation (i.e., organisation, acquired, and individuals) and grouped patent 
owners based on the number of applications they have Ô¨Åled. Then, we 
reviewed the top patent owners and deduced their historic patenting 
activity in the Ô¨Åeld. We examined RD and AD separately to understand 
better the patent landscaping related to each disease. 
3.2.1. Identifying key players in rare disease patenting over the past 20 
years 
For RD‚Äôs, from 2000 to 2021, 369 organisations, 53 individuals, and 
80 acquired organisations have played a role in the patent landscape. As 
illustrated in Fig. 3 , patenting activity has grown over the years, with or- 
ganisations being the most active, followed by individuals. The boost in 
the patenting of large organisations, mainly pharmaceutical companies, 
is ascribed to legislations like the Orphan Drug Act (ODA), introduced 
in 1983, which gave Ô¨Ånancial incentives for developing therapies for 
4 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 3. The retrospective landscape of the 
rare diseases patent corpora in the past two 
decades . The line plots indicate the growth of 
the patent documents years based on assignee 
type: organisations (blue), individuals (orange), 
and acquired (green). As expected, a large contri- 
bution is evident for organisations compared to 
others. A large boost in the Individual owners is 
seen around 2012, after which there has been a 
decline due to the legislatures. 
rare diseases [18] . On top of that, the surging patent activity within 
the Ô¨Åeld after 2012 was correlated to the establishment of the Patient 
Protection and AÔ¨Äordable Care Act (ACA) which catalysed engagement 
of investors in Ô¨Ånancing R&D for orphan drugs and diseases [19] . On 
the contrary, a decrease in independent patent applications by individ- 
uals was observed since its peak in 2013. This eÔ¨Äect could be due to 
two reasons: Ô¨Årstly, changes made in US and EU legislatures during the 
early 2000s, moving the ‚Äúprofessor‚Äôs privileges ‚Äù at IP generation to the 
universities, and secondly, professors and professionals, due to their leg- 
islation, were either hired by commercial companies or became part of 
larger academic groups [20] . 
To get a historical perspective of these patents, we selected 10 top 
patent owners and organised their patent applications based upon the 
timestamp of each patent application date, also known as the prior- 
ity date. This subset of owners consisted only of global pharmaceutical 
companies such as PÔ¨Åzer, GlaxoSmithKline, etc. ( Fig. 4 ). It is essential 
to note that many start-up and medium-sized companies have emerged 
and subsequently been absorbed by larger organisations providing them 
with the leverage of patent acquisition Ô¨Åled by the smaller companies. 
One example is Sterix Ltd., which had 33 patents and was acquired by 
Ipsen (in 2004), adding to the company‚Äôs patent portfolio. Furthermore, 
most top assignees had a decreasing patenting activity in the past years. 
For instance, global giant Takeda, a Japanese multinational pharmaceu- 
tical company, just had one compound, Luvadaxistat, out of 122 from 
the patent compound space between 2000 and 2021 that went into the 
clinical trial phase II for Friedreich‚Äôs ataxia [21] . Thus, indicating a rea- 
son for decreasing interest of Takeda in rare diseases patenting ( Fig. 4 ). 
Regardless, the top 10 assignees accounted for 44% of the 502 patent 
applications analysed, and the top 20 assignees accounted for 61%. Ad- 
ditionally, we observed the cumulative positive patenting trend for the 
top patent inventors in rare disease. The trend between 2013 and 2021, 
however, can be observed with a peak around 2016 and a gradual de- 
cline in the later years ( Supplementary Figure 1 ). 
Additionally, we looked into the correlation between the patent- 
ing activity for the top owners based on the target portfolio to iden- 
tify pharmaceutical companies that show similar target portfolios. 
We identiÔ¨Åed two clusters when correlating the target-based portfo- 
lio of the top 10 owners in rare diseases ( Fig. 5 ). One of the clus- 
ters was between SanoÔ¨Å and Ardelyx. We suspect this was due to 
their collaboration on sodium and potassium channel inhibitors (which 
include KCNK3, KCNK9 and SLC9A3), allowing them to apply for 
over 50 patents ( https://ir.ardelyx.com/news-releases/news-release- 
details/ardelyx-licenses-nap2b-phosphate-inhibitor-program-kidney ). A 
prominent target in the cluster space is DAO, with competitive patenting 
between large pharmaceutical companies like PÔ¨Åzer, Takeda, and John 
and Johnson. A number of singletons are also seen, indicating the devel- 
opment of candidates targeting isolated targets (e.g. GSK, Cleave). To- 
gether this target portfolio approach allows for identifying top patented 
targets within the indication areas and comparing patent owners‚Äô target 
portfolios. 
As mentioned, no patent assignees in the top 10 were aÔ¨Éliated with 
an academic institute. To depict the diÔ¨Äerence, we divided organisa- 
tions into two categories, industry and academia. Interestingly, a boost 
in patent applications from the academic sector was seen after 2012 has 
been tracked. ( Supplementary Figure 2A ). However, a general pos- 
itive trend in patent applications by the industry is observed denoting 
increasing interest within pharmaceutical drug discovery for novel treat- 
ments for this disease. During the same time, patent law amendments 
took place in the United States of America, commonly referred to as 
the 2011 Patent Reform Act [22] . The reformed law pointed out the 
change in the prosecution of patent applications within the U.S. Patent 
and Trademark OÔ¨Éce (USPTO) by moving from a ‚ÄúÔ¨Årst-to-invent ‚Äù to 
a ‚ÄúÔ¨Årst-to-Ô¨Åle ‚Äù system. This law thereby redeÔ¨Åned what was required 
in terms of prior art, modifying the application process in a signiÔ¨Åcant 
way. 
3.2.2. Identifying key players in Alzheimer‚Äôs disease patenting over the past 
20 years 
In Alzheimer‚Äôs disease, 10,017 organisations, 1778 individuals, and 
1386 acquired organisations have contributed towards the patenting ac- 
tivity. Similar to the rare disease patent landscape, organisations are in 
the lead compared to individuals and acquired organisations (as shown 
in Fig. 6 ). This is attributed to the exceptionally high cost involved in the 
research and development of clinical trials, which cannot be aÔ¨Äorded 
by publicly funded universities or small-scale organisations unless in 
partnerships with pharmaceuticals [23] . On the other hand, individuals 
showed an increase in patenting activity in 2011, with a peak in 2013 
and then a decline afterwards, likely due to changes in patenting laws 
made by US and EU government bodies that allowed for commercial in- 
novation rights to universities as well. Thus, individuals aÔ¨Éliated with 
universities lost their right to Ô¨Åle patents to universities, while other in- 
5 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 4. Top owners-based patent analysis in 
the Ô¨Åeld of rare diseases. Patent landscaping of 
the top 10 owners in the rare disease domain in 
descending order. The top owners were deduced 
from the In the Ô¨Ågure, it can be seen that large 
pharmaceutical companies historically active in 
rare diseases, like SanoÔ¨Å or Takeda, declined their 
patenting activity in the past few years, allowing 
other biopharmaceuticals such as GlaxoSmithK- 
line, PÔ¨Åzer, and Sage therapeutics to enter the 
Ô¨Åeld. 
Fig. 5. Target portfolio of top 10 owners in rare diseases . The hierarchically-clustered heatmap denotes the correlation distance between the top 10 rare disease 
owners based on their respective target patent landscape. The colour scale in the heatmap represents the number of patent documents associated with these targets. 
Together this clustering approach allows for the identiÔ¨Åcation of clusters, here between SanoÔ¨Å and Ardelyx and PÔ¨Åzer and Ipsen, thereby indicating overlap between 
the targeting portfolio of these pharmaceuticals. From the plot, we can also notice the focus on DAO inhibitors within the rare disease industry. 
6 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 6. Patent activity by owner type in the 
Alzheimer‚Äôs Ô¨Åeld . The line plots indicate the 
growth of the patent documents years based 
on assignee type: organisations (blue), individ- 
uals (orange), and acquired (green). Pharma- 
ceutical companies and universities are leading 
in patenting activity compared to others. Com- 
pared to the rare disease Ô¨Åeld, the contribution 
of the acquired owners is greater. A decline in 
Individual owner activity was observed post- 
2012 due to the legislature changes in US and 
EU. 
dividuals attracted pharmaceutical companies towards them and soon 
were hired by these large companies. 
We generated a retrospective perspective of the top 10 organisations 
found in Alzheimer‚Äôs patent corpora ( Fig. 7 ). Even though the total num- 
ber of patent applications was higher for Alzheimer‚Äôs disease compared 
to rare diseases, a similar trend was observed. The top patent owners 
include Roche, Bristol Myers Squibb, PÔ¨Åzer, etc., which are global phar- 
maceutical companies. There were ‚Äúpatent cliÔ¨Äs ‚Äù, where a sudden loss 
of patent rights occurs due to concomitant expirations of several patents 
at the same time [24] , within the underlying cohorts with decrements 
and increments in the patenting activity during the two decades. The 
increment denoted the increased interest of researchers in understand- 
ing the complex mechanism involved in Alzheimer‚Äôs disease. Despite the 
high investment in basic and clinical research, the mechanisms involved 
in the modulation of Alzheimer‚Äôs disease remained unclear, with a high 
attrition rate seen in clinical trials [ 25 , 26 ]. We would like to point out 
that the trend mentioned above for Alzheimer‚Äôs disease would not be 
fully concordant with the current market trends as we did not consider 
any ‚Äúbiologicals ‚Äù compounds, which have played an enormous role in 
drug discovery against Alzheimer‚Äôs disease lately [27] . A similar trend as 
that of rare diseases was observed in the cumulative patenting of the top 
patent inventors in Alzheimer‚Äôs disease. A gradual increase in activity 
was observed from 2013 with a peak around 2016 followed by a decline 
in the activity as the years came closer to the COVID-19 pandemic age 
( Supplementary Figure 1 ). 
Next, we looked at the top patent owners with Alzheimer‚Äôs dis- 
ease and plotted their target portfolio to examine whether two 
or more owners follow a similar target portfolio. Prominent col- 
laboration partners such as Novartis and Amgen have coordi- 
nated neuroscience eÔ¨Äorts and hence can be seen within a clus- 
ter in Fig. 8 ( https://www.genengnews.com/news/amgen-novartis- 
launch-neuroscience-drug-collaboration/ ). Moreover, individual com- 
panies such as Takeda are observed due to their dominance, in particu- 
lar, targeting mechanisms such as LPAR5 and SLC6A9. It is noteworthy 
that despite having common target spaces with leading pharmaceuti- 
cals, each top owner has at least one other neurodegenerative-related 
target space where it is leading with respect to the patenting landscape. 
ROCK2 for BMS, TTK for Bayer, and GCG for PÔ¨Åzer are examples of 
this case. Overall, this approach enables identiÔ¨Åcation of patent owners 
with comparable target focus and uncovers patterns in neurodegenera- 
tive drug target prioritisation. 
Similarly to the rare disease case, none of the top patent owners 
were from the academic sector, which is not surprising given the R&D 
cost involved in the case of Alzheimer‚Äôs disease [23] . Thus, we looked 
into the patenting activity of the academic sector and compared their 
growth with the industry ( Supplementary Figure 2B ). Similar to rare 
diseases, a general positive trend in patent applications by the indus- 
try is observed. An incremental rise in academic patenting activity 
was observed due to the amendment of the 2011 Patent Reform Act 
that was highlighted previously. During the same period, there was es- 
tablishment of an act in the United States, the National Alzheimer‚Äôs 
Project Act (NAPA), that promoted research and development in the 
Ô¨Åeld of Alzheimer‚Äôs ( https://www.nia.nih.gov/about/nia-and-national- 
plan-address-alzheimers-disease ). In Europe, collaborative projects in- 
volving public-private partnerships with key stakeholders from the phar- 
maceutical industry were developed. One such project was the Euro- 
pean Prevention of Alzheimer‚Äôs Dementia Consortium EPAD ( https://ep- 
ad.org/ ) which involved data collection and analysis to speed up the 
drug discovery process for the disease, and support for improving clini- 
cal trial practice and design. 
3.3. Elucidation of the research trends of targets using patent documents 
Many factors contribute to the successful discovery of small molecule 
drugs for speciÔ¨Åc therapies. One of the essential factors is the mode of 
action (MoA) of the drug in the human body, which refers to the ef- 
fect a drug has on a biological protein (also known as a target) that 
is relevant to mechanisms involved within diseased conditions. With 
the help of patent documents, we can investigate the target-based MoA 
claims within patent applications based on their eÔ¨Äect in certain indi- 
cation areas or on their importance over time from success achieved in 
clinical trials. Additionally, identifying potential disease targets, their 
prevalence, and their role in aÔ¨Äected patient populations can be useful 
in developing new intellectual property. In this section, we will focus 
only on trends in the prioritisation of targets in patent literature over 
the years, while the therapeutic usage of targets has been previously 
described [28] . 
To investigate the research trend for targets, we Ô¨Årst linked the 
patent information to targets. This was done by retrospectively connect- 
ing the patents to the targets through small molecule modulators. We 
would like to highlight that no prospective mapping of patents to targets 
based on their presence in the patent document was performed to con- 
7 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 7. Patenting activity from the top owners 
in Alzheimer‚Äôs disease. In descending order, the 
plots showcase the patenting activity of the past 
two decades for the 10 top owners. The leaders 
in the Ô¨Åeld are global pharmaceutical companies 
such as PÔ¨Åzer and BMS. All the top owners have 
been active within the Ô¨Åeld of Alzheimer‚Äôs with 
consistent patenting activity. 
Fig. 8. Target portfolio of top 10 patent owners in Alzheimer‚Äôs diseases . The hierarchically-clustered heatmap denotes the correlation distance between the top 
10 Alzheimer‚Äôs patent owners based on their respective target patent landscape. Each coloured box in the plot indicates the number of patents from the owner linked 
to the speciÔ¨Åc target. We can observe three main clusters in this plot: the Ô¨Årst is that of BMS and Bayer, the second is that of Roche and Johnson & Johnson, and the 
third is composed of Amgen and Novartis. 
Ô¨Årm the link. Similar to the patent assignee analysis, we looked into the 
prevalence of targets over time (Supplementary Tables 1 and 2) . Fur- 
thermore, we will clearly distinguish the target priorities between RD 
and AD to understand the involved targets‚Äô evolution. For both RD‚Äôs and 
AD, only the top targets, represented by the number of corresponding 
patent documents, were used to understand the target portfolio focus 
within the pharmaceutical companies. 
We Ô¨Årst started to evaluate the variations of the targets that are 
prioritised each year, to form the basis for target-centric landscaping, 
enabling us to identify targets that have been continued, diverted (to 
other targets), or halted, with respect to research, during their develop- 
ment. During this analysis, it was observed that the target perspective of 
the patent landscape was characterised by waves, which meant that not 
all targets were prioritised simultaneously (Supplementary Figure 3) . 
8 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
Fig. 9. The patenting frequency of selected targets within each disease domain. (A) Targets for rare diseases. In the case of rare diseases, we looked into three 
targets, namely DAO (red), PYGL (green), and VCP (blue), to understand the underlying market perception concerning patents. ( B) Targets for insulin metabolism- 
related neurodegenerative diseases. In the case of Alzheimer‚Äôs disease, we looked into a set of targets that play a role in insulin and sugar metabolism, namely 
RET (turquoise), INSR (orange), and SLC5A1 (violet). Each of the three targets follows a similar patenting proÔ¨Åle. ( C) Secretase-related targets in Alzheimer‚Äôs 
diseases. The major secretase enzymes related to Alzheimer‚Äôs disease include ADAM17 (pink) and BACE1 (teal), and both of them follow a diÔ¨Äerent patenting proÔ¨Åle 
despite being in the same class. ( D) Patenting proÔ¨Åle for ELANE, a target within Alzheimer‚Äôs disease. 
Thus, we looked at selected high proÔ¨Åle targets for each disease and 
compared the patent activity with the corresponding therapeutical trial 
activities to understand the correlation between the agglomerated tar- 
gets in a speciÔ¨Åc year and the preclinical research in drug discovery. 
Glycogen phosphorylase L (PYGL) was one of the high incidence tar- 
gets with 71 patent references. The mutation in the PYGL gene causes 
inhibition in the conversion of glycogen to glucose, thus, associating it 
with an autosomal recessive rare disease called glycogen storage dis- 
ease type VI (GSDVI) [29] . This key link between the mutant PYGL and 
GSDVI was the reason for its early research and patenting activity. How- 
ever, over the past years, interest in this target has gradually decreased, 
with almost no patent documents between 2014 and 2019 ( Fig. 9 A). In 
early 2019, small molecules called glucokinase activators (GKAs) were 
thought to be a potential solution for type II diabetes due to their ability 
to regulate glucose-6-phosphate and PYGL [30] . As research progressed 
on GKAs, it was found that they induced hypoglycemia, a condition char- 
acterised by decreased blood glucose levels, causing all clinical trials 
during that time to be terminated [31] . As a result, researchers refo- 
cused on the PYGL gene post-2014. 
Another illustrative target in the ranked list of targets was ATPase 
valosin-containing protein (VCP/p97). This protein plays a role in in- 
tracellular homoeostasis by regulating protein metabolism and is asso- 
ciated with multiple diseases such as Paget disease and Amyotrophic 
Lateral Sclerosis and its types [ 32 , 33 ]. However, due to the complex na- 
ture of the gene‚Äôs function in the body, research took an extended period, 
causing a dormant period in the patenting world. As soon as it gained 
interest, there was a steep increase in the number of patent documents, 
but this number soon fell ( Fig. 9 A). The key reason for this decline could 
be realistically attributed to VCP inhibitor CB-5083, a molecule devel- 
oped by Cleave Bioscience, that failed at phase-1 due to oÔ¨Ä-target eÔ¨Äects 
[34] . Subsequently, it was deduced that the covalent binding towards 
the target caused mutations that modiÔ¨Åed the morphology of protein, 
thus, making cells resistant to the drug [35] . Moreover, since the target 
is involved in cellular homoeostasis [36] , a deeper understanding of the 
MoA of drugs is needed for such targets. 
Another target that surfaced in the rare disease domain with the 
highest number of associated patent documents was d -amino acid ox- 
idase (DAO). It is a neuromodulator that was found to be involved in 
psychotic disorders [37] . This target has been active over the years from 
both the patenting ( Fig. 9 A) and scientiÔ¨Åc literature, with several clini- 
cal trials. Additionally, the discovery of the target‚Äôs role in schizophrenia 
and cognitive dysfunction, and the need for its inhibition in these condi- 
tions, is one of the reasons for its active patenting landscape [38] . How- 
ever, in the past two years, there has been a decrease in patents. This 
decline in patent activity could be ascribed to the COVID-19 pandemic, 
as global attention and resources have been focused on addressing the 
outbreak [39] . 
Interestingly, in the context of neurodegenerative diseases, some of 
the most well-known targets for Alzheimer‚Äôs, such as amyloid beta pre- 
cursor protein (APP) and tau (MAPT) [40] , were not found in the top 
target list (Supplementary Table 2). This was likely due to an ab- 
sence of publicly available bioactivity data within resources such as 
ChEMBL on these targets, as antibodies and other biologicals are not 
considered. Contrary to these, coagulation factors, such as coagulation 
factor X (F10), which have a direct link to neuro-related diseases, were 
found in the top list [41] due to several novel small molecule modu- 
lators discovered. At the top of the target list was ret proto-oncogene 
(RET), with 886 patent application documents, demonstrating an active 
patenting proÔ¨Åle ( Fig. 9 B). This activity proÔ¨Åle can be attributed to the 
growing interest and research regarding insulin and sugar metabolism 
9 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
in the brain, where the receptor RET contributes towards metabolic ho- 
moeostasis [42] . Other targets that contribute to the same mechanisms 
include insulin receptors (INSR) and glucose transporters solute carrier 
family 5 member 1 (SLC5A1), which were also found in the list later 
with an active patenting proÔ¨Åle ( Fig. 9 B). 
Secretases such as alpha-secretase (ADAM17) have gained interest 
within the pharmaceutical industry since the early 2000s due to their 
role in inhibiting amyloid beta formation [43] . Despite high patenting 
activity in the early years, there was a sharp decrease in 2005, and in- 
terest in such targets has been declining since then ( Fig. 9 C). Possible 
reasons for this decline include the failure of clinical trials for secretase 
inhibitors Lundbeck‚Äôs Flurizan and Lilly‚Äôs semagacestat in later years 
[ 44 , 45 ]. The major drawback of these compounds was their inability to 
reach the desired concentration in the brain, as they could not pass the 
blood-brain barrier, thus, not reaching long residency time. 
Other targets, such as neutrophil elastase (ELANE), also demonstrate 
patenting cliÔ¨Äs [25] . As described previously, this is correlated with ei- 
ther research activities on the target or clinical trial outcomes of drugs. 
The same pattern was observed in ELANE ( Fig. 9 D), which involved 
the development of elastase inhibitors and their advanced clinical trials 
[46] . The declining patenting activity was attributed to the identiÔ¨Åca- 
tion of multiple mutations for the targets and the involvement of these 
mutants in multiple diseases. This target complexity thus required fur- 
ther research on both the biological and drug development sides. 
Lastly, it is already known that there is a ‚Äúlag ‚Äù in the period between 
the Ô¨Åling of patent applications and the scientiÔ¨Åc research involved. We 
extrapolated this lag in the target space by looking into selected top tar- 
gets and correlating the patent applications and research publications 
over time ( Supplementary Figure 4 ). It can be observed that, on aver- 
age, there is a lag of 5 years between the research involved on a target 
(with or without disease context) and the Ô¨Åling of patents relevant to 
the target. There are indeed certain outliers to this lag period such as 
INSR, which took at least 14 years to enter into the Alzheimer‚Äôs patent- 
ing world. One reason for this could be due to the importance of the 
target on other diseases, causing it to be extensively researched in the 
early 2000s. However, only after 2009 did the study of INSR in neu- 
rodegeneration start following the recognition of type 2 diabetes as a 
risk factor for Alzheimer‚Äôs [47] . 
3.5. IdentiÔ¨Åcation of drug repurposing scenarios of diseases using patent 
documents 
As drug discovery is so resource intensive, a preliminary assessment 
of promising or under-exploited protein target and/or chemical scaf- 
fold combinations repurposing drugs could be a convenient alternative 
approach. We aimed to investigate whether drugs that have been repur- 
posed for diÔ¨Äerent therapeutic areas are also present in the patent cor- 
pora for the two disease areas. To achieve this, we clustered the patent 
documents based on the compounds they mentioned and ranked them in 
descending order of their counts. Since we were interested in repurposed 
compounds, we restricted the patent search to granted documents only. 
It is important to note that a patent application does not exclusively 
cover a single compound due to the presence of Markush structures [48] . 
These structures are a scaÔ¨Äold representation of a compound with the 
addition of variable side chains, thus making it more diÔ¨Écult for re- 
searchers to identify a speciÔ¨Åc compound via a direct search match, al- 
though commercial software tools (like SciFinder) have been developed 
to solve this problem. A single compound can also be covered by mul- 
tiple patents, as the same compound can be used for varied innovative 
features (such as disease type or treatments, physical pharmaceutical 
forms, combinations with other therapeutic compounds, etc.), allow- 
ing for independent drafting for each area. Moreover, multiple patent 
drafting does not necessarily mean the compound is used for multiple 
purposes, as they may be patents Ô¨Åled for the compound‚Äôs formulations 
or non-obvious structural modiÔ¨Åcations. Thus, a systematic case-by-case 
study needs to be done to identify such compounds and ranking of com- 
pounds based on patent documents can serve as a starting point for such 
analysis. 
Aligning our deÔ¨Ånition of repurposed compounds to a patent per- 
spective, we categorised a compound as repurposed if it was found in 
more than two granted patent documents (belonging to B or E kind 
code). This resulted in a reduced dataset of 145 repurposed compounds 
in rare diseases and 1928 in Alzheimer‚Äôs diseases, out of 585 and 
22,682 compounds, respectively. Moreover, from the entire compound 
dataset, only four compounds for rare disease compounds and 215 com- 
pounds for Alzheimer‚Äôs diseases have been tested in clinical trials (as of 
1st of Jan 2023 http://clinicaltrial.gov ) (as shown in Supplementary 
Figure 5) with minimal overlap with the dataset of repurposed com- 
pounds. This indicates that most of the compounds within the granted 
patent space under study are still in the research or pre-clinical phase, 
likely due to the limited availability of bioassay data on clinically vali- 
dated compounds in public data repositories such as ChEMBL. 
Cleave Biosciences‚Äôs CB-5083 is one of the RD repurposed drugs 
forming an interesting case study. The company had patented the com- 
pound in Europe (EP-2,875,018-B1) and the United States of Amer- 
ica (US-10,010,554-B2) as an inhibitor of VCP for cancer treatment. 
Following a phase I clinical trial, which revealed oÔ¨Ä-target activities, 
clinical development was halted [49] . Despite the unsuccessful clinical 
trial, it has made its way to the RD community regarding its poten- 
tial use in treating Paget disease, a VPC-dependant disease [32] . An- 
other example is Fosdagrocorat, a compound patented by PÔ¨Åzer as a 
glucocorticoid receptor modulator for osteoporosis (EP-2,114,888-B1). 
Research has linked the same receptor to rheumatoid arthritis [50] , 
thus making it possible to repurpose the compound for this rare dis- 
ease [51] . Upadacitinib, commonly known by the trade name Rinvoq, 
is an Abbvie-developed kinase inhibitor that has been approved by the 
FDA for the treatment of multiple diseases, such as rheumatoid arthritis 
[52] and atopic dermatitis. It inhibits the Spleen tyrosine kinase (Syk) 
(US-10,072,034-B2), which has recently been identiÔ¨Åed as a key modu- 
lator of tauopathy, a disorder involving the accumulation of Tau [53] . 
This discovery opens up the potential for the drug to be used to treat 
neurodegenerative diseases. Similar to rare diseases, we found a few 
compounds derived from the cancer domain. Sotorasib is a compound 
that inhibits a speciÔ¨Åc KRAS mutant, KRAS G12C and demonstrates anti- 
cancerous properties (US-10,519,146-B2) [54] . Several researchers have 
identiÔ¨Åed several KRAS mutants that play a role in brain and spinal- 
related haemorrhage [55] . This presents an opportunity to test the com- 
pound on multiple KRAS mutations and optimise it to create a mutant- 
speciÔ¨Åc or general-purpose compound. In summary, it is evident through 
the above examples that the mining of patent documents from a com- 
pound perspective can provide insights into how compounds that have 
been repurposed for multiple disorders beyond the scope of their origi- 
nal patents. 
3.6. Limitations and future perspective of the approach 
The current study illuminates the historical trends observed in neu- 
rodegenerative and rare disease drug discovery and research through the 
analysis of patents. However, it is important to note that the method- 
ology employed has limitations due to the lack of inclusion of ‚Äúbiolog- 
icals ‚Äù compounds such as vaccines or long peptides. One such limita- 
tion is the indirect relationship between proteins and patents, as the 
connections were made based on chemical modulators, and the initial 
proteins may not necessarily be mentioned in the patent. To address 
this, further analyses using natural language processing (NLP) methods 
to extract gene annotations in patent documents are the best alterna- 
tive. Additionally, the modulators linked to the proteins were sourced 
from open-source data repositories, such as ChEMBL. As the deposition 
of clinical candidate structures is infrequent and often only occurs after 
early clinical trials, the patent analysis may miss important compounds 
currently in development. To mitigate this, we focused on highly ac- 
tive compounds with submicromolar activity to increase the chances of 
10 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
identifying "champion" compounds in a patent. Lastly, the time range 
chosen for the analysis (2000‚Äì2021) may have skewed the overall dis- 
tribution of results, as certain compounds approved for treatment before 
2000 were not included in the analysis. For instance, JeÔ¨Ärey Cummings 
(2018) mentioned in his article that ‚ÄúAgents producing cognitive en- 
hancement may have mechanisms independent of AD-speciÔ¨Åc pathol- 
ogy (e.g., 5-HT6 antagonists) ‚Äù [56] . 5-hydroxytryptamine receptor 6 
(5-HT6) antagonists like memantine and acetylcholinesterase inhibitors 
have been approved for AD treatment and only alleviate some AD symp- 
toms by enhancing cholinergic signalling. These chemicals are not cu- 
rative and do not surface in our analysis, as they were patented before 
2000. Despite these limitations, the study aims to provide insight into 
the intellectual eÔ¨Äort required within the pharmaceutical industry to 
identify competitors‚Äô patents containing "clinical candidates" and estab- 
lish a successful "me-too" strategy. 
4. Conclusion 
Finding safe and eÔ¨Äective therapies for diseases with unmet patient 
needs is a crucial goal of pharmaceutical research. Traditionally, the 
discovery process was initiated by systematically reviewing the scien- 
tiÔ¨Åc literature for the most promising disease-linked therapeutic targets 
or pathways. Once a targeting mechanism has been selected, it would 
either be subsequently validated or eventually discarded and an alterna- 
tive strategy adopted based on new experimental insights or literature 
analysis. Additionally, assessment of target opportunities and estimating 
their potential for successful translation in development candidates is a 
core strategic activity within the pharmaceutical industry. Such analy- 
sis is driven by machine learning models trained on large multimodu- 
lar data, including toxicological eÔ¨Äects and druggability characteristics. 
Moreover, the novelty associated with the chemical structure of candi- 
date molecules is a critical aspect of patent assessment, as companies 
need to be aware of pre-existing successful scaÔ¨Äolds. This chemoinfor- 
matic integration of structural features is often a key factor in deÔ¨Åning 
medicinal chemistry strategies when optimising leads and further pro- 
gressing compounds to development stages. 
This study uses the PEMT tool to extract, analyse, and explore the 
patent landscape for rare and Alzheimer‚Äôs diseases. The results revealed 
historical trends in the past 20 years and identiÔ¨Åed key patent hold- 
ers and application dates. Such a retrospective trend paved the way for 
generating a longitudinal visualisation of the importance of the targets 
in both diseases. Additionally, the analysis showed the potential for us- 
ing patent literature in drug repurposing and annotating the clinical 
signiÔ¨Åcance of targets. Last, but not least, the study was able to iden- 
tify and reÔ¨Çect the shift between the research and patenting period in- 
volved in drug discovery. Certainly, this eÔ¨Äort cannot be assumed to 
reach the same proÔ¨Åciency as a professional patent analysis as it takes 
advantage of public databases, which themselves are limited, as dis- 
cussed in the previous sections. This paper is focused on the integration 
of public bioactivity datasets with patent applications and their analy- 
sis. We will inspect through future analyses how the patent information 
can optimise drug search within disease mechanisms networks, which 
is out of the scope of the current paper. This is just the tip of the ice- 
berg as huge eÔ¨Äort and resources need to be dedicated to standardis- 
ing the data and making them a potential source for future ML and LM 
models. 
Our work demonstrates that the PEMT tool provides a comprehen- 
sive and informative patent cohort to understand the research in the 
Ô¨Åeld of small molecule drugs. This landscape not only aligns with sci- 
entiÔ¨Åc literature but also allows for competitive intelligence analysis in 
pharmaceutical R&D. Overall, this patent landscaping approach from 
a drug discovery perspective highlights the importance of analysing 
patents and their usefulness in making decisions for future drug devel- 
opment eÔ¨Äorts. The possibility of tracking patenting activities from pub- 
licly available resources might help deÔ¨Åne strategies for target ranking 
within a therapeutic focus. Our methodology will contribute towards 
simplifying and streamlining the process of target prioritisation in drug 
discovery campaigns at a pharmaceutical company. 
Funding 
This work was supported by the German Federal Ministry of Educa- 
tion and Research (BMBF) [ 01GM2003A ] (project ‚ÄòTreatKCNQ‚Äô). 
Declaration of Competing Interest 
The authors declare that they have no known competing Ô¨Ånancial 
interests or personal relationships that could have appeared to inÔ¨Çuence 
the work reported in this paper. 
CRediT authorship contribution statement 
Yojana Gadiya: Project administration, Formal analysis, Writing 
‚Äì original draft. Philip Gribbon: Writing ‚Äì review & editing. Martin 
Hofmann-Apitius: Writing ‚Äì review & editing. Andrea Zaliani: Project 
administration, Formal analysis, Writing ‚Äì review & editing, Writing ‚Äì
original draft. 
Data availability 
The data and code is available on GitHub at https://github.com/ 
Fraunhofer- ITMP/Pharmaceutical- patent- landscaping . 
Acknowledgements 
The authors thank Daniel Domingo-Fern√°ndez, Bruce Schultz, and 
the anonymous reviewers for their comments and suggestions on the 
manuscript. We would also like to thank Bruce Schultz for providing 
the protein data for the HBP network, hosted by Fraunhofer SCAI. 
Supplementary materials 
Supplementary material associated with this article can be found, in 
the online version, at doi:10.1016/j.ailsci.2023.100069 . 
References 
[1] Walker RD. Patents as a source of scientiÔ¨Åc and technical information in developing 
nations. World Pat Inf 1988;10(1):5‚Äì10. doi: 10.1016/0172-2190(88)90210-4 . 
[2] Morgan MR, Roberts OG, Edwards AM. Ideation and implementation of an open 
science drug discovery business model‚ÄìM4K Pharma. Wellcome Open Res 2018;3. 
doi: 10.12688/wellcomeopenres.14947.1 . 
[3] Scianna M, Munaron L. Computational approaches for translational oncology: 
concepts and patents. Recent Pat Anticancer Drug Discov 2016;11(4):384‚Äì92. 
doi: 10.2174/1574892811666161003111543 . 
[4] Pan CL, Chen FC. Patent trend and competitive analysis of cancer immunother- 
apy in the United States. Hum Vaccin Immunother 2017;13(11):2583‚Äì93. 
doi: 10.1080/21645515.2017.1361074 . 
[5] Zhang T, Chen J, Jia X. IdentiÔ¨Åcation of the key Ô¨Åelds and their key technical points 
of oncology by patent analysis. PLoS ONE 2015;10(11):e0143573. doi: 10.1371/jour- 
nal.pone.0143573 . 
[6] Xiong W, Cao J, Zhou X, Du J, Nie B, Zeng Z, Li T. Design and evaluation of a pre- 
scription drug monitoring program for Chinese patent medicine based on knowledge 
graph. EvidBased Complement Alter Med 2021;2021. doi: 10.1155/2021/9970063 . 
[7] Li Q, Cheng T, Wang Y, Bryant SH. PubChem as a public resource for drug discovery. 
Drug discovery today 2010;15(23‚Äì24):1052‚Äì7. doi: 10.1016/j.drudis.2010.10.003 . 
[8] Papadatos G, Davies M, Dedman N, Chambers J, Gaulton A, Siddle J, Overington JP. 
SureChEMBL: a large-scale, chemically annotated patent document database. Nu- 
cleic Acids Res. 2016;44(D1):D1220‚Äì8. doi: 10.1093/nar/gkv1253 . 
[9] Mucke HA. What patents tell us about drug repurposing for cancer: a land- 
scape analysis. In: Seminars in cancer biology, 68. Academic Press; 2021. p. 3‚Äì7. 
doi: 10.1016/j.semcancer.2019.09.010 . 
[10] Falaguera MJ, Mestres J. Congenericity of claimed compounds in patent applica- 
tions. Molecules 2021;26(17):5253. doi: 10.3390/molecules26175253 . 
[11] Choi Y, Park S, Lee S. Identifying emerging technologies to envision a future in- 
novation ecosystem: a machine learning approach to patent data. Scientometrics 
2021;126:5431‚Äì76. doi: 10.1007/s11192-021-04001-1 . 
[12] Leach AR, Magarinos MP, Gaulton A, Felix E, Kiziloren T, Arcila R, Oprea TI. Illu- 
minating the Druggable Genome through Patent Bioactivity Data. bioRxiv , 2022-07 
2022. doi: 10.1101/2022.07.15.500187 . 
11 
Y. Gadiya, P. Gribbon, M. Hofmann-Apitius et al. 
ArtiÔ¨Åcial Intelligence in the Life Sciences 3 (2023) 100069 
[13] Gadiya, Y., Zaliani, A., Gribbon, P., & Hofmann-Apitius, M. PEMT: a patent enrich- 
ment tool for drug discovery. Bioinformatics . doi: 10.1093/bioinformatics/btac716 . 
[14] Weinreich SS, Mangon R, Sikkens JJ, Teeuw ME, Cornel MC. Orphanet: a European 
database for rare diseases. Ned Tijdschr Geneeskd 2008;152(9):518‚Äì19 . 
[15] Lage-Rupprecht V, Schultz B, Dick J, Namysl M, Zaliani A, Gebel S, Hofmann- 
Apitius M. A hybrid approach unveils drug repurposing candidates target- 
ing an Alzheimer pathophysiology mechanism. Patterns 2022;3(3):100433. 
doi: 10.1016/j.patter.2021.100433 . 
[16] Hoyt CT, Konotopez A, Ebeling C. PyBEL: a computational framework for Biological 
Expression Language. Bioinformatics 2018;34(4):703‚Äì4. doi: 10.1093/bioinformat- 
ics/btx660 . 
[17] Kabir E, Uzzaman M. A review on biological and medicinal impact of heterocyclic 
compounds. Res Chem 2022:100606. doi: 10.1016/j.rechem.2022.100606 . 
[18] Bagley N, Berger B, Chandra A, Garthwaite C, Stern AD. The Orphan Drug Act at 
35: observations and an outlook for the twenty-Ô¨Årst century. Innov. Policy Econ. 
2019;19(1):97‚Äì137. doi: 10.1086/699934 . 
[19] Stella P, Gold-von Simson G. Pharmaceutical pricing, cost containment and new 
treatments for rare diseases in children. Orphanet J Rare Dis 2014;9(1):1‚Äì4. 
doi: 10.1186/s13023-014-0152-2 . 
[20] Hvide HK, Jones BF. University innovation and the professor‚Äôs privilege. Am Eco 
Rev 2018;108(7):1860‚Äì98. doi: 10.1257/aer.20160284 . 
[21] Wang H, Norton J, Xu L, DeMartinis N, Sen R, Shah A, Lynch D. Results of a ran- 
domized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. 
Ann Clin Transl Neurol 2021;8(6):1343‚Äì52. doi: 10.1002/acn3.51373 . 
[22] Ashworth AL. Race You to the patent oÔ¨Éce: how the new patent reform act will 
aÔ¨Äect technology transfer at universities. Alb LJ Sci Tech 2012;23:383 . 
[23] Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing 
treatments for Alzheimer‚Äôs disease: a retrospective exploration. Alzheimer‚Äôs Dement 
2022;18(3):469‚Äì77. doi: 10.1002/alz.12450 . 
[24] Song CH, Han JW. Patent cliÔ¨Ä and strategic switch: exploring strategic de- 
sign possibilities in the pharmaceutical industry. Springerplus 2016;5(1):1‚Äì14. 
doi: 10.1186/s40064-016-2323-1 . 
[25] Anderson, R.M., Hadjichrysanthou, C., Evans, S., & Wong, M.M. (2017). Why 
do so many clinical trials of therapies for Alzheimer‚Äôs disease fail?. The Lancet , 
390(10110), 2327‚Äì9. 10.1016/S0140-6736(17)32399-1 . 
[26] Koynova R, Tenchov B. Natural product formulations for the prevention and treat- 
ment of Alzheimer‚Äôs disease: a patent review. Recent Pat Drug Deliv Formul 
2018;12(1):23‚Äì39. doi: 10.2174/1872211312666171207152326 . 
[27] Senior M. Fresh from the biotech pipeline: fewer approvals, but biologics gain share. 
Nat. Biotechnol. 2023;1. doi: 10.1038/s41587-022-01630-6 . 
[28] Zdrazil, B., Richter, L., Brown, N., & Guha, R. (2020). Moving targets in drug dis- 
covery. Sci Rep, 10(1), 1‚Äì15. 10.1038/s41598-020-77033-x . 
[29] Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann MW. Muta- 
tions in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type 
VI (Hers disease). Am J Hum Gene 1998;62(4):785‚Äì91. doi: 10.1086/301790 . 
[30] Matschinsky FM. Assessing the potential of glucokinase activators in diabetes ther- 
apy. Nat Rev Drug disc 2009;8(5):399‚Äì416. doi: 10.1038/nrd2850 . 
[31] Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase acti- 
vators. J Diabetes Investig 2015;6(2):124‚Äì32. doi: 10.1111/jdi.12294 . 
[32] Costantini S, Capone F, Polo A, Bagnara P, Budillon A. Valosin-Containing Protein 
(VCP)/p97: a Prognostic Biomarker and Therapeutic Target in Cancer. Int J Mol Sci 
2021;22(18):10177. doi: 10.3390/ijms221810177 . 
[33] Scarian E, Fiamingo G, Diamanti L, Palmieri I, Gagliardi S, Pansarasa O. The role 
of VCP mutations in the spectrum of amyotrophic lateral sclerosis-frontotemporal 
dementia. Front Neurol 2022;271. doi: 10.3389/fneur.2022.841394 . 
[34] Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, 
Rolfe M. The p97 inhibitor CB-5083 is a unique disrupter of protein home- 
ostasis in models of multiple myeloma. Mol. Cancer Ther. 2017;16(11):2375‚Äì86. 
doi: 10.1158/1535-7163.MCT-17-0233 . 
[35] Bastola P, Wang F, Schaich MA, Gan T, Freudenthal BD, Chou TF, Chien J. SpeciÔ¨Åc 
mutations in the D1‚ÄìD2 linker region of VCP/p97 enhance ATPase activity and con- 
fer resistance to VCP inhibitors. Cell Death Discov 2017;3(1):1‚Äì9. doi: 10.1038/cd- 
discovery.2017.65 . 
[36] Ahlstedt BA, Ganji R, Raman M. The functional importance of VCP to main- 
taining cellular protein homeostasis. Biochem. Soc. Trans. 2022;50(5):1457‚Äì69. 
doi: 10.1042/BST20220648 . 
[37] Mitchell J, Paul P, Chen HJ, Morris A, Payling M, Falchi M, de Belleroche J. Familial 
amyotrophic lateral sclerosis is associated with a mutation in d -amino acid oxidase. 
Proc Natl Acad Sci 2010;107(16):7556‚Äì61. doi: 10.1073/pnas.0914128107 . 
[38] Sacchi S, Rosini E, Pollegioni L, Molla G. d -amino acid oxidase inhibitors as a novel 
class of drugs for schizophrenia therapy. Curr pharma des 2013;19(14):2499‚Äì511. 
doi: 10.2174/1381612811319140002 . 
[39] Riccaboni M, Verginer L. The impact of the COVID-19 pandemic on scientiÔ¨Åc 
research in the life sciences. PLoS ONE 2022;17(2):e0263001. doi: 10.1371/jour- 
nal.pone.0263001 . 
[40] Kodamullil AT, Zekri F, Sood M, Hengerer B, Canard L, McHale D, Hofmann- 
Apitius M. Trial watch: tracing investment in drug development for Alzheimer dis- 
ease. Nature reviews. Drug discovery 2017;16(12):819. doi: 10.1038/nrd.2017.169 . 
[41] De Luca C, Virtuoso A, Maggio N, Papa M. Neuro-coagulopathy: blood coagula- 
tion factors in central nervous system diseases. Int J Mol Sci 2017;18(10):2128. 
doi: 10.3390/ijms18102128 . 
[42] Zhao M, Jung Y, Jiang Z, Svensson KJ. Regulation of energy metabolism by receptor 
tyrosine kinase ligands. Front Physiol 2020;11:354. doi: 10.3389/fphys.2020.00354 . 
[43] Qian M, Shen X, Wang H. The distinct role of ADAM17 in APP proteolysis 
and microglial activation related to Alzheimer‚Äôs disease. Cell. Mol. Neurobiol. 
2016;36(4):471‚Äì82. doi: 10.1007/s10571-015-0232-4 . 
[44] Wan HI, Jacobsen JS, Rutkowski JL, Feuerstein GZ. Translational medicine 
lessons from Ô¨Çurizan‚Äôs failure in Alzheimer‚Äôs disease (AD) trial: implication for 
future drug discovery and development for AD. Clin Transl Sci 2009;2(3):242. 
doi: 10.1111/j.1752-8062.2009.00121.x . 
[45] Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, JoÔ¨Äe S, Mohs R. A phase 
3 trial of semagacestat for treatment of Alzheimer‚Äôs disease. N Engl J Med 
2013;369(4):341‚Äì50. doi: 10.1056/NEJMoa1210951 . 
[46] Ahmad S, Saleem M, Riaz N, Lee YS, Diri R, Noor A, Elsebai MF. The natu- 
ral polypeptides as signiÔ¨Åcant elastase inhibitors. Front Pharmacol 2020;11:688. 
doi: 10.3389/fphar.2020.00688 . 
[47] Wang H, Wang R, Zhao Z, Ji Z, Xu S, Holscher C, Sheng S. Coexistences of in- 
sulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res. 
2009;1249:237‚Äì43. doi: 10.1016/j.brainres.2008.10.046 . 
[48] Geyer P. Markush structure searching by information professionals in the chem- 
ical industry‚Äìour views and expectations. World Pat Inf 2013;35(3):178‚Äì82. 
doi: 10.1016/j.wpi.2013.05.002 . 
[49] Leinonen H, Cheng C, Pitk√§nen M, Sander CL, Zhang J, Saeid S, Palczewski K. A 
p97/valosin-containing protein inhibitor drug CB-5083 has a potent but reversible 
oÔ¨Ä-target eÔ¨Äect on phosphodiesterase-6. J Pharmacol Exp Ther 2021;378(1):31‚Äì41. 
doi: 10.1124/jpet.120.000486 . 
[50] Schlaghecke R, Kornely E, Wollenhaupt J, Specker C. Glucocorticoid receptors in 
rheumatoid arthritis. Arthritis Rheum OÔ¨Ä J Am Coll Rheum 1992;35(7):740‚Äì4. 
doi: 10.1002/art.1780350704 . 
[51] Stock T, Fleishaker D, Wang X, Mukherjee A, Mebus C. Improved disease activity 
with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, 
in patients with rheumatoid arthritis: a Phase 2 randomized study. Int J Rheum Dis 
2017;20(8):960‚Äì70. doi: 10.1111/1756-185X.13053 . 
[52] Duggan S, Keam SJ. Upadacitinib: Ô¨Årst approval. Drugs 2019;79(16):1819‚Äì28. 
doi: 10.1007/s40265-019-01211-z . 
[53] Schweig JE, Yao H, Coppola K, Jin C, Crawford F, Mullan M, Paris D. Spleen tyrosine 
kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo. J Biol Chem 
2019;294(36):13378‚Äì95. doi: 10.1074/jbc.RA119.008033 . 
[54] Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, Singh H. FDA ap- 
proval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer 
Res 2022;28(8):1482‚Äì6. doi: 10.1158/1078-0432.CCR-21-3074 . 
[55] Hong T, Yan Y, Li J, Radovanovic I, Ma X, Shao YW, Wang Y. High prevalence of 
KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malforma- 
tions. Brain 2019;142(1):23‚Äì34. doi: 10.1093/brain/awy307 . 
[56] Cummings J. Lessons learned from Alzheimer disease: clinical trials with negative 
outcomes. Clin Transl Sci 2018;11(2):147. doi: 10.1111/cts.12491 . 
12 
